Home > Insider Trading > Filing (0001179110-15-012232)

Filing Details

Accession Number:: 0001179110-15-012232
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-08-17 17:27:06
Reporting Period:: 2015-08-13

Filing Date:: 2015-08-17
Accepted Time:: 2015-08-17 17:27:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1042074	Cymabay Therapeutics Inc.	CBAY	Pharmaceutical Preparations (2834)	943103561

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1588856	Kurt Emster Von	C/O Cymabay Therapeutics, Inc. 7999 Gateway Blvd, Suite 130 Newark CA 94560		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-08-13	31,359	$2.68	31,359	No	4	P	Direct
Common Stock	Acquisiton	2015-08-14	58,641	$2.70	90,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,600,000	Indirect	See footnote
Common Stock	17,326	Indirect	By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.675 to $2.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.68 to $2.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Consists of (i) 533,333 shares held by Abingworth Bioventures VI, LP ("ABV VI"), and (ii) 1,066,667 shares held by Abingworth Bioequities Master Fund Limited ("ABE," and collectively with ABV VI, the "Abingworth Funds").
Abingworth LLP ("ALLP") provides advisory services to the Abingworth Funds. Kurt von Emster ("Emster") is a member of ALLP. Emster may be deemed the indirect beneficial owner of the shares through his indirect interest in the Abingworth Funds. Emster disclaims beneficial ownership of the shares except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that ALLP, the Abingworth Funds, Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.